rp7214
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04680429)
Timeline
Indications
Mechanism of action
- Dihydroorotate dehydrogenaseINHIBITOR
DHODH inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05246384 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | Rhizen Pharmaceuticals SA |
| NCT05007236 | Phase 2 | Sep 20, 2021 | Incozen Therapeutics Pvt Ltd, Rhizen Pharmaceuticals SA |
| NCT04680429 | Phase 1 | Dec 31, 2020 | Rhizen Pharmaceuticals SA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rhizen Pharmaceuticals SA | For profit | 3 | 3 | 2 | 2020 |
| Incozen Therapeutics Pvt Ltd | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1